Patents Assigned to Elan Pharaceuticals, Inc.
  • Humanized anti-VLA4 immunoglobulins
    Patent number: 7435802
    Abstract: The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
    Type: Grant
    Filed: December 8, 2004
    Date of Patent: October 14, 2008
    Assignee: Elan Pharaceuticals, Inc.
    Inventors: Mary M. Bendig, Olivier J. Leger, Jose Saldanha, Tarran S. Jones, Ted A. Yednock